Advertisement
Singapore markets closed
  • Straits Times Index

    3,300.00
    -4.00 (-0.12%)
     
  • S&P 500

    5,497.68
    +10.65 (+0.19%)
     
  • Dow

    38,909.06
    +74.20 (+0.19%)
     
  • Nasdaq

    17,896.11
    +33.88 (+0.19%)
     
  • Bitcoin USD

    64,832.19
    -131.92 (-0.20%)
     
  • CMC Crypto 200

    1,347.54
    -35.12 (-2.54%)
     
  • FTSE 100

    8,264.58
    +59.47 (+0.72%)
     
  • Gold

    2,377.70
    +30.80 (+1.31%)
     
  • Crude Oil

    82.21
    +0.64 (+0.78%)
     
  • 10-Yr Bond

    4.2810
    +0.0640 (+1.52%)
     
  • Nikkei

    38,633.02
    +62.26 (+0.16%)
     
  • Hang Seng

    18,335.32
    -95.07 (-0.52%)
     
  • FTSE Bursa Malaysia

    1,592.69
    -7.10 (-0.44%)
     
  • Jakarta Composite Index

    6,819.32
    +92.40 (+1.37%)
     
  • PSE Index

    6,344.56
    -21.47 (-0.34%)
     

Dyne Therapeutics to Present at Jefferies Global Healthcare Conference

Dyne Therapeutics, Inc.
Dyne Therapeutics, Inc.

WALTHAM, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at the Jefferies Global Healthcare Conference in New York on Thursday, June 6, 2024 at 3:00 p.m. ET.

A live webcast will be available in the Investors & Media section of Dyne’s website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 90 days following the presentation.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to muscle tissue. Dyne has a broad pipeline for serious muscle diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and a preclinical program for facioscapulohumeral muscular dystrophy (FSHD). For more information, please visit https://www.dyne-tx.com/, and follow us on X, LinkedIn and Facebook.

Contact:

Dyne Therapeutics
Amy Reilly
areilly@dyne-tx.com
857-341-1203